ARTICLE | Regulation
Pilgrim's Progress
January 23, 1995 8:00 AM UTC
Commentary
Occasionally a glimmer of common sense pierces the Slough of Despond in Washington. Last week, the industry was blessed with two glimmers, as an FDA advisory panel voted not to endorse an agency proposal to make approval of drugs even harder, and the NIH continued on its course to abandoning the reasonable pricing clause in CRADAs...